Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a
clinical-stage biopharmaceutical company focused on the
development, and ultimately the commercialization, of therapeutic
drugs for both oncology and rare disease indications, today
announced that Cristina Csimma, Pharm. D., M.H.P. and Michael
Dougherty have been appointed to the Board of Directors, effective
April 10, 2019.
“Cristina and Mike are valuable additions to our Board of
Directors,” stated James Geraghty, Chairman of Idera’s Board of
Directors. “Both have had decades of experience in our
industry as operators and as strategic leaders through their
various board and leadership positions. As our company
continues to progress towards a commercial stage biotech, their
presence and leadership will be immeasurable.”
Dr. Csimma currently serves as an independent Director of
Neuralstem. Inc. and is a Board Director of T1D Exchange
(non-profit-Type 1 Diabetes). She also serves on advisory boards
including the Muscular Dystrophy Association Venture Philanthropy
Scientific Advisory Committee; the Executive Oversight Board to the
National Institutes of Health (NIH) NeuroNext Network, the Harvard
and Brigham and Women’s Hospital MRCT Center External Advisory
Board, and the TREAT-NMD Advisory Committee for Therapeutics
(TACT). Dr. Csimma previously served as a director on the
boards of Juniper Pharma, Vtesse Pharma, was the Executive Chair of
Exonics Therapeutics, and was President, founding CEO and Board
Director of Cydan Inc. She also served on the NIH Blueprint
Neurotherapeutics Network External Oversight Committee, was Vice
President of Drug Development at Virdante Pharmaceuticals Inc.,
Principal at Clarus Ventures LLC and held roles of increasing
responsibility in Clinical Development and Translational Research
at Wyeth, Genetics Institute and Dana Farber Cancer
Institute.
Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of
Science in Pharmacy from the Massachusetts College of Pharmacy and
Allied Health Sciences, as well as a Master of Health Professions
from Northeastern University.
Mr. Dougherty most recently served as the
executive chairman of Celator Pharmaceuticals until its acquisition
by Jazz Pharmaceuticals in July 2016. Previously, Mr. Dougherty was
chief executive officer and a member of the board of directors of
Kalidex Pharmaceuticals and Adolor Corporation. Mr. Dougherty
previously served in a variety of senior positions, including chief
operating officer of Genomics Collaborative, chief executive
officer and member of the board of directors of Genaera
Corporation, and chief financial officer at Centocor. He currently
serves on the board of directors at Marinus Pharmaceuticals and
Trevena, publicly traded life sciences organizations. Mr. Dougherty
also served on the board of directors for Foundation Medicine,
Inc., Aviragen Therapeutics, Inc., Cempra, Inc. and ViroPharma
Incorporated from 2004 until its acquisition by Shire in 2014.
Mr. Dougherty received a Bachelor of Science in Accounting from
Villanova University.
The company today is also announcing that Dr. Kelvin Neu of
Baker Brothers Investments, is stepping down from the Board of
Directors effective June 4, 2019. Dr. Neu has served on the
Idera Board of Directors since 2014. During his time on the
Board, Dr. Neu played an integral role in providing strategic and
scientific guidance and played an integral role in helping shape
the path that Idera is pursuing today.
“I am incredibly thankful for the time, commitment and
importantly, strategic and scientific counsel that Kelvin provided
to our company throughout his tenure,” stated Vincent Milano,
Idera’s Chief Executive Officer. “I am certain that while no longer
in a formal capacity as a member of the board of directors, our
relationship with both Kelvin and the Baker Brothers Investments
team will continue to remain incredibly strong as our largest
shareholder.”
About Idera PharmaceuticalsHarnessing the
approach of the earliest researchers in immunotherapy and the
company’s vast experience in developing proprietary immunology
platforms, Idera’s lead development program is focused on priming
the immune system to play a more powerful role in fighting cancer,
ultimately increasing the number of people who can benefit from
immunotherapy. Idera also continues to focus on the acquisition,
development and ultimate commercialization of drug candidates for
both oncology and rare disease indications characterized by small,
well-defined patient populations with serious unmet needs. To learn
more about Idera, visit www.iderapharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements, other than statements of historical fact, included
or incorporated in this press release, including statements
regarding the company’s strategy, future operations,
collaborations, cash resources, financial position, future
revenues, projected costs, prospects, clinical trials, plans and
objectives of management, are forward-looking statements. The words
“believes,” “anticipates,” “estimates,” “plans,” “expects,”
“intends,” “may,” “could,” “should,” “potential,” “likely,”
“projects,” “continue,” “will,” and “would” and similar expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.
Idera cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking
statements and you should not place undue reliance on the company’s
forward-looking statements. There are a number of important factors
that could cause Idera’s actual results to differ materially from
those indicated or implied by its forward-looking statements,
including whether the company’s cash resources will be sufficient
to fund the company’s continuing operations and the further
development of the company’s programs for the period anticipated;
whether interim results from a clinical trial will be predictive of
the final results of the trial; whether results obtained in
preclinical studies and clinical trials will be indicative of the
results that will be generated in future clinical trials; whether
products based on the company’s technology will advance into or
through the clinical trial process when anticipated or at all or
warrant submission for regulatory approval; whether such products
will receive approval from the U.S. Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the company's
products receive approval, they will be successfully distributed
and marketed; whether the Company's collaborations will be
successful; and such other important factors set forth under the
caption “Risk Factors” in the company’s Annual Report on Form 10-K
for the year ended December 31, 2018. Although Idera may elect to
do so at some point in the future, the company does not assume any
obligation to update any forward-looking statements and it
disclaims any intention or obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Investor and Media ContactRobert A. Doody
Jr.Sr. VP, Investor Relationsand Corporate CommunicationsOffice:
484-348-1677rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024